Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample

Amanda M. George, Tim D. Windsor, Bryan Rodgers

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rationale: Whether the reported poorer mental health of ecstasy users is due to a bias in endorsement of somatic symptoms has been postulated, but rarely examined. Objectives: The purpose of this study is to investigate whether levels of ecstasy use were associated with differential probabilities of endorsing somatic mental health symptoms. Methods: Current ecstasy users aged 24-30 years (n∈=∈316) were identified from a population-based Australian study. Measures included frequency of ecstasy, meth/amphetamine, and cannabis use and the Goldberg anxiety/depression symptom scales. Results: Multiple indicator, multiple cause models demonstrated no bias towards endorsing somatic symptoms with higher ecstasy use, both with and without adjustment for gender, cannabis, and meth/amphetamine use. Conclusions: Other studies using alternate measures of mental health should adopt this approach to determine if there is a bias in the endorsement of somatic symptoms among ecstasy users.

Original languageEnglish
Pages (from-to)901-909
Number of pages9
JournalPsychopharmacology
Volume214
Issue number4
DOIs
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

Mental Health
Amphetamine
Cannabis
Anxiety
Depression
Population
Medically Unexplained Symptoms

Cite this

@article{81c61dcaf2b8433fb30e656e00be073a,
title = "Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample",
abstract = "Rationale: Whether the reported poorer mental health of ecstasy users is due to a bias in endorsement of somatic symptoms has been postulated, but rarely examined. Objectives: The purpose of this study is to investigate whether levels of ecstasy use were associated with differential probabilities of endorsing somatic mental health symptoms. Methods: Current ecstasy users aged 24-30 years (n∈=∈316) were identified from a population-based Australian study. Measures included frequency of ecstasy, meth/amphetamine, and cannabis use and the Goldberg anxiety/depression symptom scales. Results: Multiple indicator, multiple cause models demonstrated no bias towards endorsing somatic symptoms with higher ecstasy use, both with and without adjustment for gender, cannabis, and meth/amphetamine use. Conclusions: Other studies using alternate measures of mental health should adopt this approach to determine if there is a bias in the endorsement of somatic symptoms among ecstasy users.",
keywords = "3,4-Methylenedioxymethamphetamine (MDMA), Anxiety, Depression, Ecstasy, General community sample, Mental health",
author = "George, {Amanda M.} and Windsor, {Tim D.} and Bryan Rodgers",
year = "2011",
doi = "10.1007/s00213-010-2100-8",
language = "English",
volume = "214",
pages = "901--909",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample. / George, Amanda M.; Windsor, Tim D.; Rodgers, Bryan.

In: Psychopharmacology, Vol. 214, No. 4, 2011, p. 901-909.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Are ecstasy users biased toward endorsing somatic mental health symptoms? Results from a general community sample

AU - George, Amanda M.

AU - Windsor, Tim D.

AU - Rodgers, Bryan

PY - 2011

Y1 - 2011

N2 - Rationale: Whether the reported poorer mental health of ecstasy users is due to a bias in endorsement of somatic symptoms has been postulated, but rarely examined. Objectives: The purpose of this study is to investigate whether levels of ecstasy use were associated with differential probabilities of endorsing somatic mental health symptoms. Methods: Current ecstasy users aged 24-30 years (n∈=∈316) were identified from a population-based Australian study. Measures included frequency of ecstasy, meth/amphetamine, and cannabis use and the Goldberg anxiety/depression symptom scales. Results: Multiple indicator, multiple cause models demonstrated no bias towards endorsing somatic symptoms with higher ecstasy use, both with and without adjustment for gender, cannabis, and meth/amphetamine use. Conclusions: Other studies using alternate measures of mental health should adopt this approach to determine if there is a bias in the endorsement of somatic symptoms among ecstasy users.

AB - Rationale: Whether the reported poorer mental health of ecstasy users is due to a bias in endorsement of somatic symptoms has been postulated, but rarely examined. Objectives: The purpose of this study is to investigate whether levels of ecstasy use were associated with differential probabilities of endorsing somatic mental health symptoms. Methods: Current ecstasy users aged 24-30 years (n∈=∈316) were identified from a population-based Australian study. Measures included frequency of ecstasy, meth/amphetamine, and cannabis use and the Goldberg anxiety/depression symptom scales. Results: Multiple indicator, multiple cause models demonstrated no bias towards endorsing somatic symptoms with higher ecstasy use, both with and without adjustment for gender, cannabis, and meth/amphetamine use. Conclusions: Other studies using alternate measures of mental health should adopt this approach to determine if there is a bias in the endorsement of somatic symptoms among ecstasy users.

KW - 3,4-Methylenedioxymethamphetamine (MDMA)

KW - Anxiety

KW - Depression

KW - Ecstasy

KW - General community sample

KW - Mental health

UR - http://www.scopus.com/inward/record.url?scp=79953664726&partnerID=8YFLogxK

U2 - 10.1007/s00213-010-2100-8

DO - 10.1007/s00213-010-2100-8

M3 - Article

VL - 214

SP - 901

EP - 909

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -